RealWorld Dynamix™: Biologic and Small Molecule New Starts in Psoriasis US 2018 Spotlight II
Spherix Global Insights collaborated with 154 US dermatologists to analyze the records of 1,010 psoriasis patients recently initiated on biologic or Otezla therapy for the first time. RealWorld Dynamix: Biologic and Small Molecule New Starts in Psoriasis reveals the most recent trends for the psoriasis biologic/Otezla new start market.
One aspect covered in detail in this study is the “courtship” between the physician and patient regarding initiating first-line biologic/small molecule therapy and the patient’s mental state about beginning treatment. The below infographic includes complimentary highlights on the metrics collected at the physician-reported and patient audit level.
Contact [email protected] for more information about the highlighted report or to see if your company already has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.